168 related articles for article (PubMed ID: 21245103)
1. Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma.
Shazeeb MS; Sotak CH; DeLeo M; Bogdanov A
Cancer Res; 2011 Mar; 71(6):2230-9. PubMed ID: 21245103
[TBL] [Abstract][Full Text] [Related]
2. MR signal amplification for imaging of the mutant EGF receptor in orthotopic human glioma model.
Shazeeb MS; Gupta S; Bogdanov A
Mol Imaging Biol; 2013 Dec; 15(6):675-84. PubMed ID: 23733229
[TBL] [Abstract][Full Text] [Related]
3. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
5. Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas.
Gibbs-Strauss SL; Samkoe KS; O'Hara JA; Davis SC; Hoopes PJ; Hasan T; Pogue BW
Acad Radiol; 2010 Jan; 17(1):7-17. PubMed ID: 19796971
[TBL] [Abstract][Full Text] [Related]
6. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions.
de Souza AL; Marra K; Gunn J; Samkoe KS; Hoopes PJ; Feldwisch J; Paulsen KD; Pogue BW
Mol Imaging Biol; 2017 Feb; 19(1):41-48. PubMed ID: 27379987
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
Zalutsky MR; Boskovitz A; Kuan CT; Pegram CN; Ayriss J; Wikstrand CJ; Buckley AF; Lipp ES; Herndon JE; McLendon RE; Bigner DD
Nucl Med Biol; 2012 Jan; 39(1):23-34. PubMed ID: 21958852
[TBL] [Abstract][Full Text] [Related]
9. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.
Golding SE; Morgan RN; Adams BR; Hawkins AJ; Povirk LF; Valerie K
Cancer Biol Ther; 2009 Apr; 8(8):730-8. PubMed ID: 19252415
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.
Takasu S; Takahashi T; Okamoto S; Oriuchi N; Nakayashiki N; Okamoto K; Muramatsu H; Hayashi T; Nakahara N; Mizuno M; Wakabayashi T; Higuchi T; Endo K; Kozaki K; Miyaishi O; Saga S; Ueda R; Yoshida J; Yoshikawa K
J Neurooncol; 2003 Jul; 63(3):247-56. PubMed ID: 12892230
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III.
Fukai J; Nishio K; Itakura T; Koizumi F
Cancer Sci; 2008 Oct; 99(10):2062-9. PubMed ID: 19016767
[TBL] [Abstract][Full Text] [Related]
12. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
13. MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors.
Davis SC; Samkoe KS; O'Hara JA; Gibbs-Strauss SL; Payne HL; Hoopes PJ; Paulsen KD; Pogue BW
Acad Radiol; 2010 Mar; 17(3):271-6. PubMed ID: 20152724
[TBL] [Abstract][Full Text] [Related]
14. Tomography of epidermal growth factor receptor binding to fluorescent Affibody in vivo studied with magnetic resonance guided fluorescence recovery in varying orthotopic glioma sizes.
Holt RW; Demers JL; Sexton KJ; Gunn JR; Davis SC; Samkoe KS; Pogue BW
J Biomed Opt; 2015 Feb; 20(2):26001. PubMed ID: 25652703
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma.
Balyasnikova IV; Ferguson SD; Sengupta S; Han Y; Lesniak MS
PLoS One; 2010 Mar; 5(3):e9750. PubMed ID: 20305783
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
Binder ZA; Thorne AH; Bakas S; Wileyto EP; Bilello M; Akbari H; Rathore S; Ha SM; Zhang L; Ferguson CJ; Dahiya S; Bi WL; Reardon DA; Idbaih A; Felsberg J; Hentschel B; Weller M; Bagley SJ; Morrissette JJD; Nasrallah MP; Ma J; Zanca C; Scott AM; Orellana L; Davatzikos C; Furnari FB; O'Rourke DM
Cancer Cell; 2018 Jul; 34(1):163-177.e7. PubMed ID: 29990498
[TBL] [Abstract][Full Text] [Related]
17. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.
Gong H; Kovar JL; Cheung L; Rosenthal EL; Olive DM
Cancer Biol Ther; 2014 Feb; 15(2):185-93. PubMed ID: 24100437
[TBL] [Abstract][Full Text] [Related]
20. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
